Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology.
R&D Tax Credit Retained In New Tax Bill
19 Dec 2017 08:49 #10818
Rodney- with the immense tax loss carry forward (NOL), which Cytori has and which exceeds its market capitalization with many multiples, this- at least for CYTX- seems very relative...
It is not so much the near-term impact on CYTX and other stem cell companies operating independently, but rather how a larger profitable BP or other medical company would view a partnership or acquisition if going forward the R&D tax credit were no longer available - obviously, that would diminish the target company's valuation and potential purchase price.